The importance of a serum creatinine increase, traditionally considered worsening renal function (WRF), during admission for acute heart failure has been recently debated, with data suggesting an interaction between congestion and creatinine changes.
B
oth an increase in serum creatinine of ≥0.3 mg/dL, traditionally defined as worsening of renal function (WRF), and persistent congestion have been shown to be associated with adverse outcomes in patients admitted for acute heart failure (HF). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Further analyses have shown the importance of decongestion, measured either through clinical signs 12 or by laboratory exams, hemoconcentration or diuretic response, [13] [14] [15] as a major predictor of outcomes. Evidence has also clarified that the clinical significance of an increase in serum creatinine differs when it occurs concomitantly with decongestion, rather than in the presence of diuretic resistance. 12, 16 Last, retrospective analyses of randomized controlled trials have shown that a reduction, rather than an increase, in serum creatinine can be associated with worse outcomes. [17] [18] [19] [20] These last trials were characterized, however, by the enrollment of patients with severe HF so that a decrease in serum creatinine could have been an index of increased central venous pressure and renal venous congestion at baseline. These results further emphasize that the interpretation of serum creatinine changes is critically dependent on the patient's fluid status. Hence, the term pseudo-WRF has been proposed to define when an increase in serum creatinine is not associated with worsening of renal function and poorer outcomes. 21 The PROTECT study (Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) was one of the first trials to apply serial measurements of creatinine in all patients from admission to day 6 or 7 and then at day 14 regardless of disease severity. 22, 23 Analysis of data from this study has shown that creatinine changes over time, assessed as trajectories of change, are associated with risks of both 180-day mortality and 60-day mortality or readmission. Namely, an increase in serum creatinine >0.1 mg/dL per day was predictive of an increased risk of death, whereas stable or decreasing serum creatinine levels were associated with reduced risk. 24 These analyses seemingly contradict previous data. However, they may be caused by differences in fluid status and response to treatment. In the current post hoc analysis of the PROTECT data, we have assessed the prognostic significance of serum creatinine changes as related with the presence of congestion in patients enrolled in PROTECT.
METHODS
The PROTECT study was a randomized, double-blind, placebo-controlled trial designed to evaluate 3 daily 4-hour intravenous infusions of rolofylline in 2033 patients hospitalized with acute decompensated HF and mild to moderate renal impairment (20-80 mL/min). 11, 12 The study was initiated as 2 identical trials, but shortly after amended to specify a combined analysis of the 2 studies. Patients at centers in North America, Israel, Europe, Argentina, and Russia were enrolled between May 2007 and January 2009. Acute decompensated HF was defined as dyspnea at rest or with minimal exertion and at least 1 sign of fluid overload: jugular venous pulse >8 cm, pulmonary rales ≥1/3 up the lung fields not clearing with cough or ≥2+ peripheral or presacral edema. Patients with BNP (B-type natriuretic peptide) <500 pg/mL or NT-proBNP (N-terminal pro-B-type natriuretic peptide) <2000 pg/mL, or systolic blood pressure <95 or >160 mm Hg were excluded. Patients were randomized within 24 hours of hospital presentation. The ethics committee at each participating center approved the protocol, and all patients provided written informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Signs and symptoms of HF were assessed before study drug initiation (day 1), then daily while hospitalized through day 6, and then on days 7 and 14. Blood samples for central laboratory hematology and chemistry measures were taken at the same time points. Patients discharged on day 6 were not required to return at day 7. Patients were contacted by telephone at days 60 and 180. Rehospitalization and deaths through day 60 were adjudicated by a blinded clinical events committee. The study treatment did not have a statistically significant effect on the study's primary efficacy end pointan ordered trichotomy defined as treatment success (based on dyspnea relief), no change (neither success nor failure), or treatment failure (death, HF readmission or in-hospital worsening HF, or persistent WRF)-at day 7. Study treatment groups also did not differ with respect to either secondary
WHAT IS NEW?
• Patients admitted with acute heart failure who experienced worsening renal function as determined by a creatinine increase of ≥0.3 mg/dL had a longer average length of hospital stay but only those patients who had significant signs of congestion.
• Patients with worsening renal function also had a greater risk of death or readmission for a cardiovascular or renal reason within 30 days of the assessment only if significantly congested at the time of the assessment.
• These associations did not vary over time for assessments made over the first week after admission.
WHAT ARE THE CLINICAL IMPLICATIONS?
• In patients admitted for acute heart failure, clinicians should pay attention to the combination of signs of persistent congestion and creatinine increase.
• When these signs occur together, they carry negative short-term prognostic implications.
efficacy end point-60-day death or rehospitalization for cardiovascular or renal reason or persistent renal impairment (creatinine increase ≥0.3 mg/dL at days 7 and 14)-or with respect to 180-day all-cause mortality.
Statistical Methods
As no difference between the rolofylline and placebo treatment groups was found with respect to any outcome, including WRF, 12, 25 the data of all patients, irrespective of drug assignment, are used in the present study.
Daily creatinine changes from baseline were categorized as representing WRF (an increase ≥0.3 mg/dL) or not. Congestion scores were computed for each study day by summing up the coded values of orthopnea (0:none, 1:1 pillow, 2:2 pillows, 3:>30°), edema (0:0, 1:1+, 2:2+, 3:3+), and jugular venous pressure (0:<6 cm, 1:6-10 cm, 2:>10 cm), if all 3 parts were available, and were then dichotomized as mild (≤2) or significant (≥3) for each study day, as previously described 26 and modified for this study (Rubio-Gracia et al 27 ). Because patients discharged on day 6 were not required to return at day 7, creatinine changes and congestion scores at day 7 were used if available and the day 6 value otherwise.
Patients were subdivided into 4 groups defined by the occurrence or not of a creatinine increase ≥0.3 mg/dL and by the presence or absence of a congestion score of ≥3 at 2-time points-day 2 (24-48 hours from hospital presentation) and day 14. Groups were compared about baseline characteristics using ANOVA (or Kruskal-Wallis test if highly skewed) for continuous variables and χ 2 test for categorical variables. The associations with clinical outcomes of a creatinine increase ≥0.3 mg/dL at each study day were then evaluated by the dichotomized congestion score at the same study day. A sensitivity analysis was conducted where congestion scores from the previous day were coupled with the creatinine changes from days 3 through 6 or 7. Clinical outcomes included the time to all-cause death or cardiovascular/renal rehospitalization) rehospitalization from the respective study day through 30 days thereafter, time to all-cause death from baseline through study day 90, and length of initial hospital stay (LOS) through study day 60 with in-hospital deaths set to a value of 61 days. Subjects who were not followed up beyond (>) the respective study day were excluded from the estimated association for that particular study day. For LOS, subjects who did not stay in hospital beyond the respective study day were also excluded. Associations, expressed as hazard ratios (HRs) or mean differences respectively, were estimated using Cox proportional hazards models for timeto-event end points and linear regression models for LOS. Because LOS was truncated in many cases, a sensitivity analysis was performed using Cox regression for time to discharge through day 60. For each study day, the models included dichotomized creatinine change, dichotomized congestion score, and their interaction as factors, from which, the effects (HRs or mean differences) of a creatinine increase ≥0.3 mg/ dL were estimated for subjects with and without significant congestion at each study day. Models were further adjusted for predictors as previously published for similar end points in PROTECT. 28, 29 Missing baseline parameters were imputed by multiple imputation with 10 imputed data sets assuming multivariate normality. Estimated effect sizes, 95% confidence intervals (CIs), and P values were combined across the multiply-imputed data sets using Rubin's algorithm. 30 Linear regression models were used to examine whether the difference in association of creatinine increase with outcomes in patients with and without significant congestion varied over time, and to obtain an estimate of the average difference in association over time, reported as the average ratio of the HRs or average difference of the mean differences between these effects over the study period. Variances for the estimated associations of creatinine increase with outcomes (log HRs or mean differences) in patients with and without significant congestion on each study day were obtained by running the models for 1000 bootstrap samples. The bootstrap estimates of the creatinine increase effect were then analyzed in a single linear regression model using the bootstrap variances and including dichotomized congestion score, study day, and the interaction of congestion score and study day as factors. If the interaction of congestion and time was nonsignificant, the interaction term was removed from the model, and the difference in the effects of creatinine increase in patients with and without significant congestion estimated from the bootstrap results. The same analyses were conducted examining a creatinine decrease ≥0.3 mg/dL. Twosided P<0.05 was considered statistically significant, without adjustment for multiple comparisons. SAS 9.3 (SAS Institute, Cary, NC) was used for analyses.
RESULTS
Of the 2033 total patients randomized, 1684 patients had both creatinine change and congestion score available at study day 2, and 1537 patients had both available at study day 14. Baseline characteristics by creatinine increase and congestion score at days 2 and 14 are shown in Tables 1 and 2, respectively. Patients with a creatinine increase of ≥0.3 mg/dL were more likely to have an event of death or cardiovascular/renal rehospitalization readmission within 30 days of the assessment if they were significantly congested at the time of assessment. Figure 1 presents multivariableadjusted HRs for a creatinine increase in patients with and without significant congestion based on estimates from individual models per study day (Table IA in the Data Supplement), with linear regression results from the bootstrap analysis overlaid. In the patients with a congestion score of ≤2, the increase in serum creatinine was never associated with worse outcomes within 30 days of the assessment; the HR estimated at day 7 from the bootstrap regression was 0.98 (95% CI, 0.76-1.27; P=0.8833). In contrast, the increase in creatinine in the patients with significant congestion was associated with an almost 1.5× higher risk of events and these HRs were statistically significant with the measurements taken at days 2, 4, and 5 (the lower bound of the CI does not include 1.00) and nearly significant at the other time points (the lower 95% confidence bound was 0.97 at day 7 and 0.96 at day 14). The HR estimated at day 7 from the bootstrap regression was 1.46 (95% CI, The effect of congestion on the association of creatinine increase with the 30-day outcome did not vary significantly over time; the ratio of HRs for a creatinine increase in patients with and without significant congestion remained constant from day 2 (24 hours from randomization) through day 14 (congestion-by-time interaction, P=0.9100). Results were similar if patients were categorized by the congestion score on the day before the creatinine measurement (Table IB and Figure I in the Data Supplement); the HR for a creatinine increase in patients with a congestion score of ≥3 on the previous day was 1.39× the HR in those with score of ≤2 (95% CI, 0.94-2.05; P=0.1020).
With respect to mortality at 90 days, a creatinine increase of ≥0.3 mg/dL was associated with a higher risk of the outcome in patients significantly congested at the time of creatinine measurement (estimated at day 7 from the bootstrap linear regression: HR, 1.94; 95% CI, 1.43-2.63; P<0.0001) than in those with no or mild congestion (estimated at day 7 from the bootstrap linear regression: HR, 1.36; 95% CI, 0.94-1.96; A creatinine increase of ≥0.3 mg/dL was associated with a longer LOS especially when noted later during the admission (Figure 3 ; Table IIIA in the Data Supplement). Also, in this case, the effect of a creatinine increase differed significantly by whether the patient had significant congestion at the time of assessment. Patients with 0 to 2 congestion score did not experience an appreciable increase in the LOS associated with a creatinine increase ≥0.3 mg/dL on any day through day 7 (Table IIIA in the Data Supplement); the mean change in LOS estimated at day 7 from the bootstrap linear regression (Figure 3) Summary statistics based on subjects who were followed up beyond day 2 and had creatinine increase from baseline and congestion score available for that study day. Results shown are mean (SD) with P value from ANOVA (F-test) for continuous variables, median (first and third quartile) with P value from Kruskal-Wallis test for continuous variables with skewed distributions, or prevalence (%) with P value from χ 2 test for categorical variables. ALT indicates alanine transferase; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and PVD, peripheral vascular disease. Figure IIIA in the Data Supplement). Analysis of the outcome as time to discharge through day 60, rather than as a continuous variable, supports this finding. A creatinine increase was associated with less likelihood of discharge through day 60 only in patients significantly congested at the time (Table IIIC and Figure IIIB in the Data Supplement).
We repeated the same analysis examining the effect of a creatinine decrease of ≥0.3 mg/dL. Few patients experienced a creatinine decrease of such magnitude; at day 2, only 23 patients with congestion score of 0 to 2 and 72 patients with congestion score of ≥3 experienced such a creatinine decrease. Patients with a creatinine decrease at nearly all time points examined experienced lower rates of all 3 outcomes of interest (30-day cardiovascular/renal readmission or death, 90-day death, and LOS), with the estimated beneficial effects of a creatinine decrease more pronounced in patients with congestion score of ≥3; however, as the numbers of patients were small in these subgroups the estimated effects of a creatinine decrease, differences in creatinine decrease effects between patients with and without significant congestion, and any variation in the difference between congestion groups with respect to the creatinine decrease effect over time all failed to reach statistical significance (Figures IV through VI in the Data Supplement).
DISCUSSION
This analysis of PROTECT shows that an increase in serum creatinine is associated with poorer outcomes only in the patients with significant congestion, defined Summary statistics based on subjects who were followed up beyond day 14 and had creatinine increase from baseline and congestion score available for that study day. Results shown are mean (SD) with P value from ANOVA (F-test) for continuous variables, median (first and third quartile) with P value from Kruskal-Wallis test for continuous variables with skewed distributions, or prevalence (%) with P value from χ 2 test for categorical variables. ALT indicates alanine transferase; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and PVD, peripheral vascular disease. as a score of ≥3, at the time of the serum creatinine measurements. The difference in the effect of serum creatinine increases by congestion score was significant for the composite outcome at 30 days but did not reach statistical significance when day 90 mortality was considered, likely because of insufficient events. This differential effect of a creatinine increase did not vary with respect to the time of the clinical assessment. Similar to outcomes, LOS was longer in those patients with an increase in serum creatinine and concomitant congestion but not in those with a congestion score of 0 to 2. The clinical significance of serum creatinine changes in acute HF is still controversial with either its increase or a reduction associated with poorer outcomes. 21 Some of this heterogeneity of result may relate to the fact that when single time points are compared with the baseline assessments or the assessments are done using specific cutoffs, the result can be less significant (Tables I through  III in the Data Supplement) . We have previously shown using a single center database that the importance of creatinine changes is influenced by the fluid status. 12 However, this study was small and relied on creatinine measurements that were not uniformly performed at predefined time points. In the current post hoc analysis of the PRO-TECT database, we confirm and expand these findings. First, creatinine increases of ≥0.3 mg/dL are associated with adverse outcomes mainly in patients who are significantly congested at the time of creatinine measurement. This finding would suggest that creatinine bumps because of excessive dehydration, such as after diuretic therapy, do not necessarily carry negative prognostic implications while similar increases in patients who have persistent congestion despite diuretic therapy, and who are likely diuretic resistant, are ominous signs. This finding is in line with clinical common wisdom and previous studies suggesting that patients who remain congested and display deterioration in renal function despite optimal therapy during an acute HF admission, have a more dire prognosis, especially when it comes to short-term events. Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at day 1). Adjusted hazard ratios (HRs) for the effect of creatinine increase with 95% confidence intervals (CIs) were estimated from Cox proportional hazards models for each study day that included the effects of creatinine increase, congestion category, and their interaction, in subjects who were followed up beyond days 2, 3, 4, 5, 7, or 14, respectively, and had creatinine change from baseline and congestion score available for that study day. HRs >1 signify a harmful effect of creatinine increase. The ratio of the creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The congestion-by-time interaction P value was estimated from a model that also included the interaction effect. Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at day 1). Adjusted hazard ratios (HRs) for the effect of creatinine increase with 95% confidence intervals (CIs) were estimated from Cox proportional hazards models for each study day that included the effects of creatinine increase, congestion category, and their interaction, in subjects who were followed up beyond days 2, 3, 4, 5, 7, or 14, respectively, and had creatinine change from baseline and congestion score available for that study day. HRs >1 signify a harmful effect of creatinine increase. The ratio of the creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The congestion-by-time interaction P value was estimated from a model that also included the interaction effect.
An interaction between the effect of increases in serum creatinine and congestion on LOS was also found in the present analysis. Patients congested at the time of serum creatinine measurements had very large increases in LOS, whereas little to no increase in LOS occurred in patients who were not significantly congested at the time of their measurements. These data are consistent with the poorer outcomes associated with WRF in the patients who develop worsening HF, and hence congestion, during hospitalization. They also confirm the finding that creatinine changes significantly affect the clinical course and outcomes of patients with acute HF only when associated with significant congestion. This finding may have implications in analyzing results of intervention clinical studies, as the assumption that all creatinine increases are associated with worse outcome may not be true, and hence some creatinine changes in response to interventions may not be signifiers of future adverse outcome.
In the current analysis, we did not observe an association between creatinine decreases and more adverse outcomes, a finding shown in other studies. 17, 20 To the contrary, we noted numerically smaller hazards for 30-day death or cardiovascular/renal readmission and 90-day mortality and shorter LOS in those patients. However, as noted above, only a few patients had creatinine decreases of 0.3 mg/dL or more, and none of the associations examined reached statistical significance. As with increases in creatinine, the difference between our data and those previously published may be because of chance-as none of these effects were statistically significant-or because of ascertainment bias in other studies. In PROTECT, creatinine was measured daily systematically, and hence there was no bias toward sicker patients having more creatinine measurements, enabling, possibly, a more objective assessment of the associations between creatinine changes and adverse outcomes and their interactions with congestion.
Limitations
The current analysis is a post hoc analysis of the PRO-TECT study and as such should be regarded with caution and should be confirmed in larger prospective studies. Congestion scores were determined using a simple method. It is possible that the result would have benefited from better quantitative methods of congestion assessment. Analyses of the associations of creatinine increase with outcomes over time in patients with and without significant congestion were conducted on group-level data and might not be representative of individual patient trajectories.
Conclusions
In this post hoc analysis of the PROTECT study, creatinine increases of ≥0.3 mg/dL were found to be associated with longer length of admission and a higher risk of death or readmission for cardiovascular or renal reason within 30 days only in patients who at the time of creatinine measurement were significantly congested. Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at day 1). Adjusted mean differences for the effect of creatinine increase with 95% confidence intervals (CIs) were estimated from linear regression models for each study day that included the effects of creatinine increase, congestion category, and their interaction, in subjects who were followed up beyond days 2, 3, 4, 5, or 7, respectively, and had creatinine change from baseline and congestion score available for that study day. Mean differences >0 signify a longer length of hospital stay in patients with a creatinine increase. The difference in creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The congestion-by-time interaction P value was estimated from a model that also included the interaction effect. 
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